New York, USA, July 01, 2024 (GLOBE NEWSWIRE) -- DelveInsight’s report provides comprehensive global coverage of pipeline advanced kidney cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the advanced kidney cancer pipeline domain. Request a sample and discover the recent advances in advanced kidney cancer treatment drugs @ The advanced kidney cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage advanced kidney cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the advanced kidney cancer clinical trial landscape. Advanced kidney cancer, also referred to as advanced renal cell carcinoma, is the predominant form of kidney cancer, constituting over 90% of renal cancers in adults.
Additional varieties include transitional cell carcinomas of the renal pelvis, which exhibit similar characteristics to bladder cancers, and renal sarcoma, a less common kidney tumor. The primary risk factor for renal cell carcinoma (RCC) is smoking tobacco products like cigarettes and cigars, while obesity, particularly among women, also poses a significant risk. Administering systemic treatment for advanced or metastatic RCC necessitates oncologists well-versed in the condition, medication, side effects, drug int.
